Pharmaceutical preparations company · D8 · FY ends Mar · Revenue $2M · -153.97% margin
The business is unprofitable at the operating level (-153.97% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 9.7% YoY. Margins deteriorated 23.5pp alongside, both lines moving the wrong way.
Operating margin contracted 23.5pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$2M
▼ -9.7% YoY
Net Income (TTM)
-$3M
▼ -6.6% YoY
Op. Margin
-153.97%
▼ -23.5pp YoY
ROIC
-13.56%
▼ -0.4pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$2M
▼ -21.6% YoY
Net Debt
-$17M
Net Cash Position
Cash & Equiv.
$18M
5Y CAGR: -19.5%
5Y CAGR: +12.7%
Continue Research